



Horizon Europe

THE NEXT EU RESEARCH & INNOVATION INVESTMENT PROGRAMME (2021 – 2027)

#HorizonEU

Irene Norstedt, acting Director
Research & Innovation DG, People Directorate

Working Together for the Future of European Health Research
Brussels, 31 January 2020

Research and Innovation



Towards the launch of Horizon Europe




Towards the launch of Horizon Europe – cascade of pending decision-making in 2020



Horizon Europe: Preliminary structure (€ 94.1 bn)



Commission proposal for synergies with other Union programmes



Orientations towards the first Strategic Plan 2021-2024

Targeted Impacts of the Health Cluster

- 1. Staying healthy in a rapidly changing society;**
- 2. Living and working in a health-promoting environment;**
- 3. Tackling diseases and reducing disease burden;**
- 4. Ensuring access to innovative, sustainable and high-quality healthcare**
- 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**
- 6. Maintaining an innovative, sustainable and globally competitive health industry**



Health Cluster Partnership Candidates

Institutional Partnerships (Article 185 and Article 187 TFEU)

2021 - Innovative Health Initiative (ex-IMI2)

2021 - EU-Africa Global Health (ex-EDCTP2)

Co-funded Partnerships

2021/22 - Partnership on Assessment of Risk of Chemicals (PARC)

2022/23 - Personalised Medicine

2022/23 - Health and Care Systems Transformation

2023/24 - Rare Diseases

2024/25 - One Health AMR

2024/25 - Fostering an ERA for Health research

↳ call year / start year



Innovative Health Initiative (IMI2 successor)

- Accelerate the **development of safer and more effective innovative healthcare interventions** that respond to **unmet public health needs**, and that **can be taken up** by healthcare systems
BY
 - European collaborative platform for precompetitive and integrative R&I **facilitating technology integration** to:
 - ↳ advance science and contribute to the **development of innovative health solutions**
 - ↳ strengthen **competitiveness** of Europe's health tech industry
 - ↳ incentivize industry to **invest in unmet public health needs**
 - ↳ shorten the **time-to-market** of innovative products and services
 - ↳ Contribute to **improved health outcomes** and to the **sustainability of the healthcare systems**.
- THROUGH
- An **institutionalised** European Partnership (Art 187) as of **2021** between the **EU** and the **European health-related industries** for pharmaceuticals, diagnostics, medical devices, imaging, biotech and digital health



EU-Africa Global Health Partnership (EDCTP2 successor)

- To **reduce social and economic burden of infectious diseases** in sub-Saharan Africa and in Europe (e.g. tuberculosis and HIV/AIDS in Eastern Europe), thereby contributing to SDG3
- AND
- To **increase health security in sub-Saharan Africa and Europe**, in particular in the context of climate change
- BY
- **accelerating the development** of effective, safe, accessible, suitable and affordable **health technologies**
 - **improving health systems interventions** for infectious diseases
 - considering co-morbidities and antimicrobial resistance
- THROUGH
- An **institutionalised or co-funded** European Partnership as of **2021** between **EU member states, sub-Saharan African countries** and the **EU**



The Mission Board for Cancer

Top-level independent experts from:

- **research, academia and medicine**
- **industry and innovation**
- **patient associations and NGOs**
- **international agencies**



Walter Ricciardi
Professor of Hygiene and Public Health at the Catholic University of the Sacred Heart in Rome
Chair



Christine Chomienne
Professor of Cellular Biology at the Université Paris Diderot, Paris
Vice-Chair

https://ec.europa.eu/info/files/members-mission-board-cancer_en



Mission Board's timelines



September 2019- End January 2020

6 Board meetings to define the outline of the mission to be discussed with stakeholders

Meeting with Member States and ITRE committee

February 2020 – June 2020

Further Board meetings to identify the first of one or more possible missions

Stakeholders and citizens engagement to define, with Board and Assembly, the research and innovation activities that will contribute to achieving the mission and be funded via the Horizon Europe work programme for 2021-2022.

In Brussels: meeting with Assembly (February) & stakeholders (March)

In each Member State: by at least one Board member



Next steps

- Continuous co-creation process to prepare first Horizon Europe Strategic Plan 2021-2024 and Work Programme 2021-2022
- Preparation of Partnerships
- Mission Board on Cancer to carry out stakeholders and citizens engagement
- Next European R&I Days in September 2020, Brussels

